Zevra Therapeutics (ZVRA) Other Non-Current Assets (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Other Non-Current Assets of $143000.0 for Q1 2026, down 51.19% on a YoY basis from $293000.0 in Q1 2025, and little changed quarter-over-quarter from $143000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Other Non-Current Assets for 13 years, with the latest figure at $143000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 51.19% year-over-year to $143000.0; the trailing twelve-month figure through Mar 2026 stood at $143000.0 (down 51.19% YoY), and the FY2025 full-year result was $143000.0, down 62.76% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $143000.0, roughly flat from $143000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.8 million in Q1 2024, with the low at $53000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $361625.0 across 5 years, with a median of $186500.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 87.9% — and 2024, when it jumped 3269.81%.
- Zevra Therapeutics' Other Non-Current Assets stood at $53000.0 in 2022, then soared by 77.36% to $94000.0 in 2023, then soared by 308.51% to $384000.0 in 2024, then sank by 62.76% to $143000.0 in 2025, then changed by 0.0% to $143000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $143000.0 (Q1 2026), $143000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 143,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | 384,000.00 |
| Sep 30, 2024 | 512,000.00 |
| Jun 30, 2024 | 875,000.00 |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 94,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 439,000.00 |
| Mar 31, 2022 | 437,000.00 |
| Dec 31, 2021 | 438,000.00 |
| Sep 30, 2021 | 439,000.00 |
| Jun 30, 2021 | 437,000.00 |
| Mar 31, 2021 | 437,000.00 |